Published in final edited form as:

Biochem Biophys Res Commun. 2014 July 18; 450(1): 851–856. doi:10.1016/j.bbrc.2014.06.074.

HMGB1-DNA Complex-induced Autophagy Limits AIM2 Inflammasome Activation through RAGE

Liying Liu^{a,b}, Minghua Yang^b, Rui Kang^c, Yan Yu^{b,c}, Yunpen Dai^a, Fei Gao^a, Hongmei Wang^a, Xiaojun Sun^a, Xiuli Li^a, Jianhua Li^d, Haichao Wang^d, Lizhi Cao^{b,*}, and Daolin Tang^{c,*}

^aDepartment of Pediatrics, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, China

^bDepartment of Pediatrics, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China

^cDepartment of Surgery, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15219, USA

^dThe Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, New York 11030, USA

Abstract

High mobility group box 1 (HMGB1) is a prototype damage-associated molecular pattern (DAMP) that can induce inflammatory and immune responses alone as well as in combination with other molecules such as DNA. However, the intricate molecular mechanisms underlying HMGB1-DNA complex-mediated innate immune response remains largely elusive. In this study, we demonstrated that HMGB1-DNA complex initially induced absent in melanoma 2 (AIM2)-dependent inflammasome activation, and promoted rapid release of inflammasome-dependent early proinflammatory cytokines such as interleukin 1 β (IL-1 β). Subsequently, HMGB1-DNA complex stimulated an ATG5-dependent cellular degradation process, autophagy, which was paralleled by a cessation of AIM2 inflammasome activation and IL-1 β release. These HMGB1-DNA complex-induced inflammasome activation and autophagy were both dependent on the receptor for advanced glycation endproducts (RAGE) that recognizes a wide array of ligands (including HMGB1 and DNA). Thus, autophagy may function as a negative counter-regulatory mechanism for HMGB1-DNA complex-induced inflammasome activation, and provide a checkpoint to limit the development of inflammation.

© 2014 Elsevier Inc. All rights reserved.

*Address correspondence and reprint requests to: Lizhi Cao, Department of Pediatrics, Xiangya Hospital, Central South University, 110 Xiangya Road Changsha, Hunan 410008, China; Phone:+86-731-84327208; Fax:+86-731-84327922; lizhicao@gmail.com or Daolin Tang, G.27C, Hillman Cancer Center, 5117 Centre Ave, Pittsburgh PA, 15213, USA; Phone:+1-412-623-1211; Fax: +1-412-623-1212; tangd2@upmc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of interest The authors declare no conflicts of interest or financial interests.

Keywords

inflammasome; autophagy; HMGB1; RAGE; AIM2; DNA

---

1. Introduction

Damage-associated molecular patterns (DAMPs) are host-derived molecules released from dead, dying, or injured cells. They mediate both immunogenic and tolerogenic cell death, and participate in the regulation of the innate immune response [1,2]. Although the list of DAMPs is growing, high mobility group box 1 (HMGB1) is the most widely-studied and best characterized DAMP. HMGB1 is structurally composed of two DNA-binding domains (box A and box B) and an acidic tail modulating DNA binding. HMGB1 is normally present in the nucleus and acts as an architectural protein with DNA binding and bending activity, which plays a specific role in sustaining chromatin structure and function. However, HMGB1 can translocate from the nucleus to the cytosol and then release to the extracellular space in an active or passive manner [3,4]. Once released, HMGB1 selectively binds to various receptors (e.g., receptor for advanced glycation endproducts [RAGE] and Toll-like receptors [TLRs]) in different cells, and mediates inflammatory responses either by itself or in combination with other molecules [5,6]. In particular, extracellular HMGB1 can bind to various types of DNA, including host genomic, mitochondrial, and microbial DNA, to form a complex to enhance the innate immune response to nucleic acids [7,8,9]. However, the molecular mechanisms underlying the HMGB1-DNA complex-mediated innate immune response still remains largely elusive.

Inflammasomes are innate inflammatory protein complexes of pro-caspase 1, adaptor proteins (e.g., apoptosis-associated speck-like protein containing a CARD, ASC) and a member of the PYHIN family (e.g., the absent in melanoma 2, AIM2). The assembly of inflammasome enables the activation of caspase-1 and the production of interleukin 1 β (IL-1 β), an important proinflammatory cytokine in human disease [10]. Carrying two oligonucleotide-binding domains, AIM2 can function as a DNA sensor and activate inflammasome in response to cytoplasmic DNA [11,12]. In this study, we describe a novel regulatory mechanism for the HMGB1-DNA complex-mediated innate immune response. We demonstrated that HMGB1-DNA complex initially induced AIM2-dependent inflammasome activation and IL-1 β release, and subsequently stimulated ATG5-dependent autophagy. Although both processes were dependent on the availability of RAGE, the subsequent autophagy may function as a negative counter-regulatory mechanism for the initial inflammasome activation, and provide a checkpoint to limit the development of inflammation.

2. Methods

2.1 Reagents

The antibodies to DNA-dependent activator of IFN-regulatory factors (DAI), leucine-rich repeat (in FLII) interacting protein 1 (LRRFIP1), AIM2, TLR4, and RAGE were obtained from Abcam (Cambridge, MA, USA). The antibodies to actin, microtubule-associated

protein 1 light chain 3 (LC3), and ATG5 were obtained from Cell Signaling Technology (Danvers, MA, USA). Poly(dA:dT)/LyoVec™ was obtained from InvivoGen (San Diego, CA, USA). High purity recombinant HMGB1 protein was generated as previously described [13].

2.2 Cell culture

THP-1 and HL-60 cell lines were obtained from ATCC and cultured in RPMI-1640 Medium or Iscove's Modified Dulbecco's Medium (Life Technologies, USA) with 10% heat-inactivated FBS, 2 mM glutamine, and antibiotic-antimycotic mix in a humidified incubator with 5% CO₂ and 95% air.

2.3 Measurement of IL-1 β release

IL-1 β released into cell culture supernatants was evaluated using an enzyme-linked immunoabsorbent assay (ELISA) kit from R&D Systems, Inc. (Minneapolis, MN, USA) according to the manufacturer's instructions.

2.4 Measurement of caspase 1 activation

Caspase 1 activation in cell lysis was evaluated using a Caspase 1 Assay Kit (Colorimetric) from Abcam according to the manufacturer's instructions. The assay is based on spectrophotometric detection of the chromophore p-nitroanilide (p-NA) after cleavage from the labeled substrate YVAD-p-NA.

2.5 RNAi

Short hairpin RNA (shRNA) against human DAI, LRRFIP1, AIM2, ATG5, TLR4, and RAGE were obtained from Sigma (St. Louis, MO, USA) and were transfected into cells using lentiviral-mediated transfection (Sigma) according to the manufacturer's instructions. Detection of knockdown was assayed by Western blot.

2.6 Western blotting analysis

Cells were lysed in 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, and 1% NP40 supplemented with a protease inhibitor (Complete Mini EDTA-free; Roche, Indianapolis, IN, USA) and phosphatase inhibitor mixture II (Sigma) [14]. Thirty micrograms of protein per lane was run on a denaturing 10% SDS-PAGE gel and subsequently transferred to polyvinylidene fluoride membranes via semidry transfer. After blocking the membrane at room temperature for three hours, the membrane was incubated overnight at 4 °C with various primary antibodies. After incubation with peroxidase-conjugated secondary antibodies for one hour at 25°C, the signals were visualized using enhanced chemiluminescence (Pierce, Rockford, IL, USA).

2.7 Statistical analysis

Data are expressed as means $\pm$ SD. Significance of differences between groups was determined by two-tailed Student's t test or ANOVA LSD test. A *p*-value < 0.05 was considered significant.

3. Results

3.1 HMGB1 enhances DNA-induced inflammasome activation in human monocytic cells

Poly(dA:dT), a repetitive synthetic double-stranded DNA (dsDNA) sequence of poly(dA-dT)•poly(dT-dA), can trigger inflammasome-mediated IL-1 β production [15]. Given that a previous study demonstrated that HMGB1 can directly bind to poly(dA:dT) *in vitro* [16], we therefore examined whether exogenous HMGB1 would affect poly(dA:dT)-induced caspase 1 activation and IL-1 β release in human monocytic cells (THP-1 and HL-60). By itself, HMGB1 triggered significant caspase 1 activation and IL-1 β release within 3 h only when given at high (5 μ g/ml), but not low dose (200 ng/ml), doses (Figure 1A and 1B). However, at low doses, HMGB1 significantly enhanced poly(dA:dT)-induced caspase 1 activation and IL-1 β release within 3 h, but not anymore at a late stage (8-24 h) (Figure 1A and 1B). Thus, there is a synergistic effect between low dose HMGB1 and dsDNA in triggering inflammasome activation and IL-1 β release at an early stage.

3.2 AIM2 is required for HMGB1-DNA complex-mediated inflammasome activation

Poly(dA:dT) is recognized by several cytosolic DNA sensors, including DAI [17], LRRFIP1 [18], and AIM2 [15]. To determine whether all these cytosolic DNA sensors were responsible for HMGB1-DNA complex-mediated inflammasome activation, we transfected THP-1 cells with specific shRNA targeting DAI, LRRFIP1, or AIM2, respectively (Figure 2A). The knockdown of AIM2, but not DAI or LRRFIP1, significantly impaired HMGB1-poly(dA:dT)-induced caspase 1 activation and IL-1 β release in THP-1 cells (Figure 2B). Similarly, the knockdown of AIM2 by shRNA in HL-60 cells (Figure 2C) also inhibited HMGB1-poly(dA:dT)-induced caspase 1 activation and IL-1 β release (Figure 2D). Collectively, these findings suggest an essential role for AIM2 in HMGB1-DNA complex-mediated inflammasome activation.

3.3 RAGE is required for HMGB1-DNA complex-mediated inflammasome activation

HMGB1 is recognized by several cell surface receptors such as RAGE and TLR4 [5]. To determine which receptor is required for HMGB1-DNA complex-mediated inflammasome activation, we transfected THP-1 cells with specific shRNA targeting RAGE or TLR4, respectively (Figure 3A). The knockdown of RAGE, but not TLR4, significantly attenuated HMGB1-poly(dA:dT)-induced caspase 1 activation and IL-1 β release (Figure 3B). Similarly, the suppression of RAGE expression by shRNA in HL-60 cells (Figure 3C) also impaired HMGB1-poly(dA:dT)-induced caspase 1 activation and IL-1 β release (Figure 3D). These findings suggest that RAGE is important for HMGB1-DNA complex-mediated inflammasome activation.

3.4 Autophagy limits HMGB1-DNA complex-mediated AIM2 inflammasome activation

Autophagy is generally a programmed survival mechanism in response to stress; however, excessive autophagy can cause cell death [19,20]. Autophagy can be measured by tracking the level of conversion of LC3-I to LC3-II. In particular, LC3-II levels correlate with autophagosome formation due to its association with the autophagosome membrane [21]. Consistent with our previous findings [22,23], we found that exogenous HMGB1

significantly increased LC3-II levels only at a late stage (24 h) and when given at a high dose (Figure 4A). However, at relative low doses, HMGB1 enhanced poly(dA:dT)-mediated elevation of LC3-II production at 24 h (Figure 4A), suggesting a synergistic effect between low dose HMGB1 and dsDNA in triggering autophagy.

To understand the possible relationship between HMGB1-DNA complex-induced inflammasome activation and autophagy, we transfected THP1 cells with shRNA targeting key signaling molecules of these processes. The knockdown of AIM2 resulted in a reduction of IL-1 β release (Figure 2), but not LC3-II production, in response to HMGB1-DNA complex (Figure 4B). In contrast, the knockdown of the autophagic regulator ATG5 inhibited LC3-II expression and prolonged IL-1 β release to 24 h following stimulation with HMGB1-DNA complex (Figure 4C). These findings suggest that the activation of autophagy at the late stage may limit the extent and timing of the HMGB1-DNA complex-mediated AIM2 inflammasome activation. This mechanism may explain why IL-1 β release is only observed during an early stage of monocyte activation. In addition, we observed that the knockdown of RAGE impaired HMGB1-DNA complex-induced IL-1 β release (Figure 3) and LC3-II production (Figure 4D), suggesting an important role for RAGE in HMGB1-DNA complex-induced inflammasome activation and autophagy (Figure 4E).

4. Discussion

HMGB1 is a prototype DAMP that can induce inflammatory and immune responses by itself as well as in combination with other molecules [6]. Growing evidence has pointed to a correlative and causative relationship between serum HMGB1 and the development of many human diseases, including inflammatory, autoimmune, and neurodegenerative diseases and cancers [24,25]. Thus, it is important to understand the mechanism of HMGB1-mediated innate immune responses under pathophysiological conditions. In this study, we provided the first evidence that HMGB1-DNA complex can activate both injury (inflammasome) and anti-injury (autophagy) mechanisms in human monocytic cell lines. The activation of autophagy at the late stage may have limited the extent of HMGB1-DNA-mediated inflammasome activation and cytokine IL-1 β release. These findings therefore identified a novel negative feedback regulatory mechanism for controlling HMGB1 activity in the innate immune response.

Inflammasomes are cytosolic multiprotein complexes that include an inflammasome sensor molecule, the adaptor protein ASC, and caspase 1. They play an important role in monitoring pathogen-associated molecular pattern molecules (PAMPs), DAMPs, or other cellular alarms, and activate programmed cellular immune responses such as caspase 1 activation and the release of pro-inflammatory cytokines (e.g., IL-1 β) [10]. The concentrations of serum HMGB1 in patients can easily reach 200 ng/ml [26]. By itself, however, HMGB1 fails to trigger inflammasome activation when given at lower doses (200 ng/ml). If given at higher doses or in combination with DNA, HMGB1 can effectively stimulates AIM2-dependent inflammasome activation as manifested by increased caspase 1 activation and IL-1 β release. These findings support the recent notion that pure recombinant HMGB1 has low or no immune activity and only acts as a DAMP when HMGB1 binds with other proteins or molecules [6]. It is not yet known whether HMGB1-DNA complex also

promotes HMGB1 release through activating inflammasome, which has been suggested as a key regulatory mechanism of HMGB1 release [27,28]. If so, it would suggest cross-regulatory relationship between HMGB1 release and inflammasome activation in innate immune responses.

Recently, a large number of studies have suggested that both DAMPs and PAMPs can activate autophagy [29]; whereas dysregulated autophagy is linked to inflammation and immunity [30]. For instance, we have recently proposed HMGB1 as a positive regulator of autophagy, and HMGB1-mediated autophagy increases chemotherapy resistance in several tumors [22,23,31,32,33]. Consistently, the conditional knockout of HMGB1 in the pancreas, liver, or myeloid cells renders mice more sensitive to injurious [34,35] and infectious insults [36] partly through inhibition of autophagy [36] and upregulation of mitochondrial injury [35] and DNA damage [34]. Our current study now indicates that the induction of autophagic response may provide a negative feedback regulation of early inflammasome signaling elicited by HMGB1-DNA complex. This possibility is supported by previous reports that the impairment of autophagy promoted caspase 1 activation and release of inflammasome-dependent cytokines [37,38,39]. Indeed, autophagy can limit inflammasome activation at multiple levels [39,40,41] such as by eliminating damaged mitochondria (to prevent mitochondrial DNA release) [42], removing active inflammasomes [38][39], and destroying cytoplasmic HMGB1 [43,44]. Thus, autophagy dysfunction is causatively linked to the aberrant immune response, although the role of autophagy in inflammation and immunity is both dynamic and highly complex.

As a cell surface receptor for multiple ligands (including HMGB1 and DNA) [45], RAGE is involved in the initiation and propagation of inflammatory responses. Consistently, the genetic disruption of RAGE expression renders animals resistant to lethal systemic inflammatory insults such as sepsis [46]. Indeed, RAGE increases innate immune responses to HMGB1 and CpG-rich dsDNA [8], and is essential for the AIM2-dependent immune response to HMGB1 and poly(dA:dT) dsDNA. It has supported an exciting possibility that RAGE serves as a central receptor for innate recognition of HMGB1-DNA complexes.

In summary, our findings show that autophagy functions as a negative regulator of HMGB1-DNA-induced AIM2-dependent inflammasome activation. This work also reinforces the important role of RAGE in regulating the host response to extracellular HMGB1 and dsDNA.

Acknowledgments

We thank Christine Heiner (Department of Surgery, University of Pittsburgh) for her critical reading of the manuscript. This work was supported by grants from The National Natural Sciences Foundation of China (81200378 to L.L.; 31171328 to L.C.; 81270616 to Y.Y.; 81100359 to M.Y.), the National Institutes of Health (R01CA160417 to D.T.; R01AT005076 and R01GM063075 to H.W.) and a 2013 Pancreatic Cancer Action Network-AACR Career Development Award (Grant Number 13-20-25-TANG).

Abbreviations

AIM2   absent in melanoma 2

DAMP	damage-associated molecular pattern
DAI	DNA-dependent activator of IFN-regulatory factors
dsDNA	synthetic double-stranded DNA
HMGB1	high mobility group box 1
IL-1β	interleukin 1 β
LRRFIP1	leucine-rich repeat (in FLII) interacting protein 1
LC3	microtubule-associated protein 1 light chain 3
PAMP	pathogen-associated molecular pattern molecule
RAGE	the receptor for advanced glycation endproducts
shRNA	short hairpin RNA
TLR	Toll-like receptor

References

- [1]. Hou W, Zhang Q, Yan Z, Chen R, Zeh Iii HJ, Kang R, Lotze MT, Tang D. Strange attractors: DAMPs and autophagy link tumor cell death and immunity. *Cell death & disease*. 2013; 4:e966. [PubMed: 24336086]
- [2]. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. *Cell*. 140:798–804. [PubMed: 20303871]
- [3]. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. *Science*. 1999; 285:248–251. [PubMed: 10398600]
- [4]. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. *Nature*. 2002; 418:191–195. [PubMed: 12110890]
- [5]. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. *Nat Rev Immunol*. 2005; 5:331–342. [PubMed: 15803152]
- [6]. Bianchi ME. HMGB1 loves company. *J Leukoc Biol*. 2009; 86:573–576. [PubMed: 19414536]
- [7]. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J, Musco G, Sitia G, Yap GS, Wan Y, Biron CA, Bianchi ME, Wang H, Chu WM. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. *Blood*. 2007
- [8]. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. *Nat Immunol*. 2007; 8:487–496. [PubMed: 17417641]
- [9]. Yanai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H, Nakasato M, Lu Y, Hangai S, Koshiba R, Savitsky D, Ronfani L, Akira S, Bianchi ME, Honda K, Tamura T, Kodama T, Taniguchi T. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. *Nature*. 2009; 462:99–103. [PubMed: 19890330]
- [10]. Schroder K. J. Tschopp, The inflammasomes, *Cell*. 2010; 140:821–832.
- [11]. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. *Nature*. 2009; 458:509–513. [PubMed: 19158676]
- [12]. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, Hornung V, Vogel SN, Szomolanyi-Tsuda E, Fitzgerald KA. The AIM2

inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. *Nat Immunol.* 2010; 11:395–402. [PubMed: 20351692]

- [13]. Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, Qiang X, Harris HE, Czura CJ, Wang H, Ulloa L, Warren HS, Moldawer LL, Fink MP, Andersson U, Tracey KJ, Yang H. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. *Mol Med.* 2003; 9:37–45. [PubMed: 12765338]
- [14]. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ 3rd, Lotze MT. Endogenous HMGB1 regulates autophagy. *J Cell Biol.* 2010; 190:881–892. [PubMed: 20819940]
- [15]. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, Latz E, Fitzgerald KA. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. *Nature.* 2009; 458:514–518. [PubMed: 19158675]
- [16]. Muller S, Bianchi ME, Knapp S. Thermodynamics of HMGB1 interaction with duplex DNA. *Biochemistry.* 2001; 40:10254–10261. [PubMed: 11513603]
- [17]. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, Lu Y, Miyagishi M, Kodama T, Honda K, Ohba Y, Taniguchi T. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. *Nature.* 2007; 448:501–505. [PubMed: 17618271]
- [18]. Yang P, An H, Liu X, Wen M, Zheng Y, Rui Y, Cao X. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. *Nat Immunol.* 2010; 11:487–494. [PubMed: 20453844]
- [19]. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. *Mol Cell.* 2010; 40:280–293. [PubMed: 20965422]
- [20]. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. *Science.* 2000; 290:1717–1721. [PubMed: 11099404]
- [21]. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. *Embo J.* 2000; 19:5720–5728. [PubMed: 11060023]
- [22]. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, Benschof R, Sparvero LJ, Amoscato AA, Tracey KJ, Zeh HJ, Lotze MT. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. *Oncogene.* 2010; 29:5299–5310. [PubMed: 20622903]
- [23]. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Lotze MT, Tang D, Cao L. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. *Leukemia.* 2011; 25:23–31. [PubMed: 20927132]
- [24]. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. *Annu Rev Immunol.* 2011; 29:139–162. [PubMed: 21219181]
- [25]. Kang R, Zhang Q, Zeh HJ 3rd, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? *Clin Cancer Res.* 2013; 19:4046–4057. [PubMed: 23723299]
- [26]. Angus DC, Yang L, Kong L, Kellum JA, Delude RL, Tracey KJ, Weissfeld L. Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis*. *Crit Care Med.* 2007
- [27]. Kang R, Tang D. PKR-dependent inflammatory signals. *Sci Signal.* 2012; 5:pe47. [PubMed: 23092889]
- [28]. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundback P, Valdes-Ferrer SI, Olofsson PS, Kalb T, Roth J, Zou Y, Erlandsson-Harris H, Yang H, Ting JP, Wang H, Andersson U, Antoine DJ, Chavan SS, Hotamisligil GS, Tracey KJ. Novel role of PKR in inflammasome activation and HMGB1 release. *Nature.* 2012; 488:670–674. [PubMed: 22801494]
- [29]. Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. *Immunol Rev.* 2012; 249:158–175. [PubMed: 22889221]
- [30]. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. *Nature.* 2011; 469:323–335. [PubMed: 21248839]
- [31]. Tang D, Kang R, Livesey KM, Zeh HJ 3rd, Lotze MT. High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. *Antioxid Redox Signal.* 2011; 15:2185–2195. [PubMed: 21395369]

- [32]. Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L, Tang D. HMGB1 promotes drug resistance in osteosarcoma. *Cancer Res.* 2012; 72:230–238. [PubMed: 22102692]
- [33]. Livesey KM, Kang R, Vernon P, Buchser W, Loughran P, Watkins SC, Zhang L, Manfredi JJ, Zeh HJ 3rd, Li L, Lotze MT, Tang D. p53/HMGB1 complexes regulate autophagy and apoptosis. *Cancer Res.* 2012; 72:1996–2005. [PubMed: 22345153]
- [34]. Kang R, Zhang Q, Hou W, Yan Z, Chen R, Bonaroti J, Bansal P, Billiar TR, Tsung A, Wang Q, Bartlett DL, Whitcomb DC, Chang EB, Zhu X, Wang H, Lu B, Tracey KJ, Cao L, Fan XG, Lotze MT, Zeh HJ 3rd, Tang D. Intracellular Hmgb1 Inhibits Inflammatory Nucleosome Release and Limits Acute Pancreatitis in Mice. *Gastroenterology.* 2013
- [35]. Huang H, Nace GW, McDonald KA, Tai S, Klune JR, Rosborough BR, Ding Q, Loughran P, Zhu X, Beer-Stolz D, Chang EB, Billiar T, Tsung A. Hepatocyte specific HMGB1 deletion worsens the injury in liver ischemia/reperfusion: A role for intracellular HMGB1 in cellular protection. *Hepatology.* 2013
- [36]. Yanai H, Matsuda A, An J, Koshiba R, Nishio J, Negishi H, Ikushima H, Onoe T, Ohdan H, Yoshida N, Taniguchi T. Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection. *Proc Natl Acad Sci U S A.* 2013; 110:20699–20704. [PubMed: 24302768]
- [37]. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, Omori H, Noda T, Yamamoto N, Komatsu M, Tanaka K, Kawai T, Tsujimura T, Takeuchi O, Yoshimori T, Akira S. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. *Nature.* 2008; 456:264–268. [PubMed: 18849965]
- [38]. Lassen KG, Kuballa P, Conway KL, Patel KK, Becker CE, Peloquin JM, Villablanca EJ, Norman JM, Liu TC, Heath RJ, Becker ML, Fagbami L, Horn H, Mercer J, Yilmaz OH, Jaffe JD, Shamji AF, Bhan AK, Carr SA, Daly MJ, Virgin HW, Schreiber SL, Stappenbeck TS, Xavier RJ. Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense. *Proc Natl Acad Sci U S A.* 2014
- [39]. Shi CS, Shenderov K, Huang NN, Kabat J, Abu-Asab M, Fitzgerald KA, Sher A, Kehrl JH. Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. *Nat Immunol.* 2012; 13:255–263. [PubMed: 22286270]
- [40]. Dupont N, Jiang S, Pilli M, Ornatowski W, Bhattacharya D, Deretic V. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1beta. *Embo J.* 2011; 30:4701–4711. [PubMed: 22068051]
- [41]. Harris J, Hartman M, Roche C, Zeng SG, O'Shea A, Sharp FA, Lambe EM, Creagh EM, Golenbock DT, Tschopp J, Kornfeld H, Fitzgerald KA, Lavelle EC. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. *J Biol Chem.* 2011; 286:9587–9597. [PubMed: 21228274]
- [42]. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, Englert JA, Rabinovitch M, Cernadas M, Kim HP, Fitzgerald KA, Ryter SW, Choi AM. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. *Nat Immunol.* 2011; 12:222–230. [PubMed: 21151103]
- [43]. Zhang Q, Kang R, Zeh HJ 3rd, Lotze MT, Tang D. DAMPs and autophagy: cellular adaptation to injury and unscheduled cell death. *Autophagy.* 2013; 9:451–458. [PubMed: 23388380]
- [44]. Li W, Zhu S, Li J, Assa A, Jundoria A, Xu J, Fan S, Eissa NT, Tracey KJ, Sama AE, Wang H. EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. *Biochem Pharmacol.* 2011; 81:1152–1163. [PubMed: 21371444]
- [45]. Sirois CM, Jin T, Miller AL, Bertheloot D, Nakamura H, Horvath GL, Mian A, Jiang J, Schrum J, Bossaller L, Pelka K, Garbi N, Brewah Y, Tian J, Chang C, Chowdhury PS, Sims GP, Kolbeck R, Coyle AJ, Humbles AA, Xiao TS, Latz E. RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. *J Exp Med.* 2013; 210:2447–2463. [PubMed: 24081950]
- [46]. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Grone HJ, Kurschus FC, Schmidt AM, Yan SD, Martin E, Schleicher E, Stern DM, Hammerling GG, Nawroth PP, Arnold B. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. *J Clin Invest.* 2004; 113:1641–1650. [PubMed: 15173891]

Highlights

- HMGB1-DNA complex induces AIM2-dependent inflammasome activation at the early stage
- HMGB1-DNA complex stimulates ATG5-dependent autophagy at the late stage
- RAGE regulates both HMGB1-DNA complex-induced inflammasome activation and autophagy
- Upregulated autophagy inhibits HMGB1-DNA complex-induced inflammasome activation

Figure 1. HMGB1 enhances DNA-induced inflammasome activation in human monocytic cells THP-1 and HL-60 cells were treated with HMGB1 (5 μg/ml or 200 ng/ml) in the absence and presence of 1 μg/ml Poly(dA:dT)/LyoVec™ for three to 24 hours, and then caspase 1 activity (A) and IL-1β release (B) were analyzed as described in Methods (n=3, * $P < 0.05$). “AU”: arbitrary units.

Figure 2. AIM2 is required for HMGB1-DNA complex-mediated inflammasome activation THP-1 (A, B) and HL-60 cells (C, D) were transfected with indicated shRNA for 48 hours and then treated with HMGB1 (200 ng/ml) plus 1 μ g/ml Poly(dA:dT)/LyoVec^{TM} for three hours ("HMGB1/dA:dT"). Caspase 1 activity and IL-1 β release (B and D) were analyzed as described in Methods (n=3, * $P < 0.05$ versus control shRNA group). "AU": arbitrary units.

Figure 3. RAGE is required for HMGB1-DNA complex-mediated inflammasome activation THP-1 (A, B) and HL-60 cells (C, D) were transfected with indicated shRNA for 48 hours and then treated with HMGB1 (200 ng/ml) plus 1μg/ml Poly(dA:dT)/LyoVec™ for three hours (“HMGB1/dA:dT”). Caspase 1 activity and IL-1β release (B and D) were analyzed as described in Methods (n=3, * $P < 0.05$ versus control shRNA group). “AU”: arbitrary units.

Figure 4. Autophagy limits HMGB1-DNA complex-mediated AIM2 inflammasome activation (A) Analysis of LC3 by Western blot in THP-1 cells after HMGB1 (200 ng/ml or 1 μ g/ml) or HMGB1 (200 ng/ml) plus 1 μ g/ml Poly(dA:dT)/LyoVec™ (“HMGB1/dA:dT) for three to 24 hours. (B-D) After transfection with AIM2 shRNA (B), ATG5 shRNA (C), RAGE shRNA (D), or control shRNA for 48 hours, cells were treated with HMGB1 (200 ng/ml) plus 1 μ g/ml Poly(dA:dT)/LyoVec™ (“HMGB1/dA:dT) for 24 hours. Total protein extracts were used for Western blot analysis. IL-1 β release (C) was analyzed using ELISA (n=3, * P < 0.05 versus control shRNA group). (E) Schematic of the mechanism by which HMGB1-DNA complex modulates the inflammatory response by regulating inflammasome activation and the autophagic response at the early and late stages, respectively.